Howard D - Search Results

1

Prospective allometric scaling: does the emperor have clothes?

Bonate PL, Howard D. Bonate PL, et al. Among authors: howard d. J Clin Pharmacol. 2000 Apr;40(4):335-40. doi: 10.1177/00912700022009017. J Clin Pharmacol. 2000. PMID: 10761158

2

Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics.

Cutler NR, Seifert RD, Schleman MM, Sramek JJ, Szylleyko OJ, Howard DR, Barchowsky A, Wardle TS, Brass EP. Cutler NR, et al. Among authors: howard dr. Clin Pharmacol Ther. 1995 Jul;58(1):54-61. doi: 10.1016/0009-9236(95)90072-1. Clin Pharmacol Ther. 1995. PMID: 7628183 Clinical Trial.

3

Clinical pharmacology and pharmacogenetics of thiopurines.

Sahasranaman S, Howard D, Roy S. Sahasranaman S, et al. Among authors: howard d. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. doi: 10.1007/s00228-008-0478-6. Epub 2008 May 28. Eur J Clin Pharmacol. 2008. PMID: 18506437 Review.

4

Prospective allometric scaling: does the emperor have clothes?

Bonate PL, Howard D. Bonate PL, et al. Among authors: howard d. J Clin Pharmacol. 2000 Jun;40(6):665-70; discussion 671-6. J Clin Pharmacol. 2000. PMID: 10868318

5

Rebuttal to Mahmood.

Bonate PL, Howard D. Bonate PL, et al. Among authors: howard d. J Clin Pharmacol. 2000 Apr;40(4):345-6. doi: 10.1177/00912700022009035. J Clin Pharmacol. 2000. PMID: 10761160 No abstract available.

6

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.

He YL, Ligueros-Saylan M, Sunkara G, Sabo R, Zhao C, Wang Y, Campestrini J, Pommier F, Dole K, Marion A, Dole WP, Howard D. He YL, et al. Among authors: howard d. J Clin Pharmacol. 2008 Jan;48(1):85-95. doi: 10.1177/0091270007307880. Epub 2007 Nov 6. J Clin Pharmacol. 2008. PMID: 17986525 Clinical Trial.

7

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.

Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, Howard D. Chakraborty A, et al. Among authors: howard d. J Clin Pharmacol. 2013 Dec;53(12):1240-51. doi: 10.1002/jcph.162. Epub 2013 Sep 30. J Clin Pharmacol. 2013. PMID: 24122883 Clinical Trial.

8

Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.

Sunkara G, Sabo R, Wang Y, He YL, Campestrini J, Rosenberg M, Howard D, Dole WP. Sunkara G, et al. Among authors: howard d. J Clin Pharmacol. 2007 Sep;47(9):1152-8. doi: 10.1177/0091270007304313. Epub 2007 Jul 26. J Clin Pharmacol. 2007. PMID: 17656620 Clinical Trial.

9

Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.

Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. Vaidyanathan S, et al. Among authors: howard d. J Clin Pharmacol. 2007 Apr;47(4):453-60. doi: 10.1177/0091270006297921. J Clin Pharmacol. 2007. PMID: 17389554 Clinical Trial.

10

Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.

Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP. Jarugula V, et al. Among authors: howard d. J Clin Pharmacol. 2010 Dec;50(12):1358-66. doi: 10.1177/0091270009359525. Epub 2010 Feb 11. J Clin Pharmacol. 2010. PMID: 20150520

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results